Introduction: In the Indian setting, antimicrobial resistance in is a considerable problem, especially in intensive care units (ICUs). Due to the limited data, clinicians are left with very few choices except polymyxins for treating serious infections caused by . There is sparse data regarding the local mechanisms of resistance.
View Article and Find Full Text PDFIntroduction: Isavuconazole is an emerging therapeutic option for invasive infections caused by molds, especially aspergillosis and mucormycosis. Isavuconazole has predictable pharmacokinetics and good bioavailability. These attributes have led to some doubts regarding the need for therapeutic drug monitoring (TDM).
View Article and Find Full Text PDFObjectives: Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. The delayed release (DR) tablet of posaconazole has been shown to have a superior pharmacokinetic profile in comparison with the oral suspension.
Methods: We retrospectively analyzed the factors associated with posaconazole levels <1.
Coronavirus Disease (COVID-19) associated fungal infections including pulmonary aspergillosis, mucormycosis and other invasive fungal infections have been increasingly described in the current pandemic. osteomyelitis is a rare clinical form of aspergillosis. Most cases of osteomyelitis are reported in immunocompromised patients.
View Article and Find Full Text PDF